<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331473</url>
  </required_header>
  <id_info>
    <org_study_id>PROVENON01</org_study_id>
    <nct_id>NCT01331473</nct_id>
  </id_info>
  <brief_title>PROximal Protection VErsus NON-Protection in Carotid Artery Stenting</brief_title>
  <acronym>PROVENON</acronym>
  <official_title>PROximal Protection VErsus NON-Protection in Carotid Artery Stenting (PROVENON Study) A Randomized Prospective MRI-based Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saarland University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saarland University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the incidence of new ischemic brain injury detected with magnetic resonance
      imaging (MRI) after carotid artery stenting in patients treated with and without proximal
      cerebral protection (Gore Flow Reversal System).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      The purpose of this study is to compare the rate of new ischemic brain injury detectable on
      MRI after carotid artery stenting between patients treated with proximal cerebral protection
      (Gore Flow Reversal System) and without cerebral protection.

      Secondary Objective:

      Impact of MRI-morphology of atherosclerotic plaque to the rate of new hyperintense diffusion
      weighted imaging (DWI) lesion on the post-treatment scan and to the rate of ipsilateral
      stroke or death.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging</measure>
    <time_frame>Day 1-3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral stroke (ischaemic stroke, intracerebral bleeding or both, with symptoms lasting more than 24 h) or death between treatment and 30 days after treatment</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success of the procedure</measure>
    <time_frame>Day 0</time_frame>
    <description>Subjects (both groups) who due to technical reaseons are unable to performe carotid artery stenting will be considered as technical failures.
Subjects who are unable to tolerate flow reversal (in group 2) and have their procedures completed without embolic protection or other methods will be also considered as technical failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access site vascular complications, defined as need for surgical repair or blood transfusion</measure>
    <time_frame>Day 0-7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Carotid Artery Stenting without Protection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carotid Artery Stenting with Proximal Protection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid Artery Stenting with Proximal Protection</intervention_name>
    <description>Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System</description>
    <arm_group_label>Carotid Artery Stenting with Proximal Protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid Artery Stenting without Protection</intervention_name>
    <description>Carotid artery angioplasty and stenting without cerebral embolic protection</description>
    <arm_group_label>Carotid Artery Stenting without Protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female ≥ 18 years old;

          -  Suitable/Eligible for carotid artery revascularization;

          -  Significant artery stenosis in symptomatic patients defined as ≥ 50% of the artery
             diameter (%DS) or asymptomatic ≥ 80 %DS by angiography. Symptomatic is defined as a
             carotid artery stenosis associated with ipsilateral transient ischemic attack (TIA),
             amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to
             enrollment.

          -  Adequate clinical conditions to perform DW-MRI.

          -  Ability of the individual to understand the character and the consequences of clinical
             trial.

          -  Signed and dated informed consent provided before the beginning of any intervention.

          -  Negative pregnancy test (serum or urine) and contraception use for any woman of
             childbearing age. Systematic contraceptives (oral, implant, injection) and dia-phragm
             or condoms with spermicidal are considered reliable. Women who have undergone
             bilateral oophorectomy or/and hysterectomy or women status post-menopausal for at
             least two years are eligible for this trial.

        Exclusion Criteria:

          -  Intracranial hemorrhage, hemorrhagic stroke, or stroke with mass effect demonstrated
             on CT scan or MRI within 30 days of the index procedure.

          -  Persisting ischemic stroke (defined as either a score &gt; 15 on the NIH stroke scale, a
             Rankin score &gt; 3 or a Barthel score &lt; 60 measured within one week prior to study
             entry).

          -  Intracranial mass lesion (i.e., abscess, tumor, or other infection).

          -  peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding the
             use of catheter-based techniques required for successful results.

          -  Lactation.

          -  Arterio-venous malformation in the territory of the target carotid artery.

          -  Any disease or medication that affects local hemostasis,

          -  Participation in other clinical trials during the present clinical trial or within the
             last month.

          -  Medical or psychological condition that would not permit completion of the trial or
             signing of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Reith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panagiotis Papanagiotou, MD</last_name>
    <phone>+49684116</phone>
    <phone_ext>24302</phone_ext>
    <email>provenon.study@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Roth, MD</last_name>
    <phone>+49684116</phone>
    <phone_ext>24302</phone_ext>
    <email>provenon.study@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Diagnostic and Interventional Neuroradiology</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis Papanagiotou, MD</last_name>
      <phone>49684116</phone>
      <phone_ext>24302</phone_ext>
      <email>provenon.study@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Christian Roth, MD</last_name>
      <phone>49684116</phone>
      <phone_ext>24302</phone_ext>
      <email>provenon.study@me.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Reith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Panagiotis Papanagiotou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Roth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Grunwald IQ, Papanagiotou P, Roth C, Fassbender K, Karp K, Krick C, Schieber H, Müller M, Haass A, Reith W. Lesion load in unprotected carotid artery stenting. Neuroradiology. 2009 May;51(5):313-7. doi: 10.1007/s00234-008-0491-6. Epub 2009 Feb 6.</citation>
    <PMID>19198823</PMID>
  </reference>
  <reference>
    <citation>Grunwald IQ, Papanagiotou P, Struffert T, Politi M, Krick C, Romaike BF, Ahlhelm F, Reith W. Reversal of flow during carotid artery stenting: use of the Parodi antiembolism system. Neuroradiology. 2007 Mar;49(3):237-41. Epub 2007 Jan 5.</citation>
    <PMID>17205314</PMID>
  </reference>
  <reference>
    <citation>Kastrup A, Nägele T, Gröschel K, Schmidt F, Vogler E, Schulz J, Ernemann U. Incidence of new brain lesions after carotid stenting with and without cerebral protection. Stroke. 2006 Sep;37(9):2312-6. Epub 2006 Aug 3.</citation>
    <PMID>16888277</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Wolfgang Reith</name_title>
    <organization>Department of Diagnostic and Interventional Neuroradiology</organization>
  </responsible_party>
  <keyword>Carotid Artery</keyword>
  <keyword>Stenting</keyword>
  <keyword>CAS</keyword>
  <keyword>proximal protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

